Bayer (BAYN) Makes SUNHARBO Available in the U.S. at $748.50 per 30-Day Supply
Bayer (BAYN) has launched SUNHARBO in the U.S. at $748.50 per 30-day supply. The drug's approval was based on Phase 3 trial results showing a 6.2% stroke rate versus 8.4% with placebo. Sales data is not yet available.
How this was made

The 30-second read
Why it matters
The launch price sets a premium benchmark in the stroke‑prevention market, creating both revenue upside and uptake risk.
Market read
First report of a new, high‑priced drug launch from a major pharma company.
What to watch
Potential insurance coverage decisions and competitive pipeline drugs.
Background
Bayer's SUNHARBO (asundexian) received FDA approval after Phase 3 showed reduced ischemic stroke rates versus placebo.
Ticker impact
Bayer announced its stroke‑prevention drug SUNHARBO is now available in the U.S. with a list price of $748.50 per 30‑day supply.
likely pressure as the market prices in the costly new drug launch
Bayer is a large‑cap pharma; a new, expensive product can affect revenue expectations and stock valuation.
Market effects
May influence other stroke‑prevention drug makers and biotech investors.
U.S. pharma market sees a new high‑priced entrant.
Limited to Bayer and its peers; no broad market shift expected.
Counterpoint
If reimbursement is secured, the drug could boost Bayer's earnings despite the high price.
Key entities
- CompanyBayer
German pharmaceutical giant launching SUNHARBO in the U.S.
